Synthesis of β-CF2-d-Mannopyranosides and β-CF2-d-Galactopyranosides by Reformatsky Addition onto 5-Ketohexoses

Navnath P. Karche; Camille Pierry; Florent Poulain; Hassan Oulyadi; Eric Leclerc; Xavier Pannecoucke; Jean-Charles Quirion

doi:10.1055/s-2006-958414

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2007(1): 0123-0126
DOI: 10.1055/s-2006-958414

LETTER

Synthesis of β-CF ₂-d-Mannopyranosides and β-CF ₂-d-Galactopyranosides by Reformatsky Addition onto 5-Ketohexoses

Navnath P. Karche, Camille Pierry, Florent Poulain, Hassan Oulyadi, Eric Leclerc*, Xavier Pannecoucke, Jean-Charles Quirion
Laboratoire d’Hétérochimie Organique and Laboratoire de Résonance Magnétique Nucléaire, UMR 6014 CNRS, IRCOF, INSA et Université de Rouen, 1 rue Tesnière, 76821 Mont Saint-Aignan Cedex, France
Fax: +33(2)35522959; e-Mail: eric.leclerc@insa-rouen.fr;

Further Information

Publication History

Received 13 October 2006
Publication Date:
20 December 2006 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

The first synthesis of β-CF ₂-d-manno- and β-CF ₂-d-galactopyranosylesters 1a and 1b is reported. It involves an oxidation-Reformatsky addition sequence on carbohydrate-derived diols and a dehydroxylation of the resulting cyclized compounds. The expected β-CF ₂-d-glycoside and an undesired β-CF ₂-l-glycoside are obtained from this sequence. An application of this methodology to the synthesis of some fluorinated pseudo-glycopeptides, potential selectin inhibitors, is also described.

Key words

fluorinated C-glycosides - CF ₂-glycopeptides - biomimetic synthesis - addition reactions - stereoselectivity

References and Notes

1 Essentials of Carbohydrate Chemistry and Biochemistry 2nd ed.: Lindshorst TK. Wiley-VCH; Weinheim: 2002.

Google Scholar
2a Keding SJ. Danishefsky SJ. In Carbohydrate-Based Drug Discovery Vol. 1: Wong C.-H. Wiley-VCH; Weinheim: 2003. p.381-406

Crossref Google Scholar
2b Dziadek S. Hobel A. Schmitt E. Kunz H. Angew. Chem. Int. Ed. 2005, 44: 7630

Crossref Google Scholar
2c Buskas T. Ingale S. Boons G.-J. . Angew. Chem. Int. Ed. 2005, 44: 5985

Crossref Google Scholar
3a Postema MHD. Piper JL. Betts RL. Synlett 2005, 1345

Google Scholar
3b Marcaurelle LA. Bertozzi CR. Chem. Eur. J. 1999, 5: 1384

Google Scholar
3c Sears P. Wong C.-H. Angew. Chem. Int. Ed. 1999, 38: 2300

Google Scholar
4a Marcotte S. D’Hooge F. Ramadas S. Pannecoucke X. Feasson C. Quirion J.-C. Tetrahedron Lett. 2001, 42: 5879

Article in Thieme Connect Google Scholar
4b Quirion J.-C, Pannecoucke X, D’Hooge F, Marcotte S, Castelot-Deliencourt G, Jubault P, and Gouge V. inventors; WO 014928A2.

Article in Thieme Connect
4c Cuenca AB. D’Hooge F. Gouge V. Castelot-Deliencourt G. Oulyadi H. Leclerc E. Jubault P. Pannecoucke X. Quirion J.-C. Synlett 2005, 2627

Article in Thieme Connect Google Scholar
5a Kirsch P. Modern Fluoroorganic Chemistry Wiley-VCH; Weinheim: 2004.

Crossref Google Scholar
5b Burke TR. Lee K. Acc. Chem. Res. 2003, 36: 426

Crossref Google Scholar
5c Blackburn GM. Jakeman DL. Ivory AJ. Williamson MP. Bioorg. Med. Chem. Lett. 1994, 4: 2573

Crossref Google Scholar
For pioneering or recent syntheses of CF ₂-glycopyranosides, see:
6a Houlton JS. Motherwell WB. Ross BC. Tozer MJ. Williams DJ. Slawin AMZ. Tetrahedron 1993, 49: 8087

Article in Thieme Connect Google Scholar
6b Berber H. Brigaud T. Lefebvre O. Plantier-Royon R. Portella C. Chem. Eur. J. 2001, 7: 903

Article in Thieme Connect Google Scholar
6c Wegert A. Miethchen R. Hein M. Reinke H. Synthesis 2005, 1850

Article in Thieme Connect Google Scholar
7a Adinolfi M. Barone G. De Lorenzo F. Iadonisi A. Synlett 1999, 336

Google Scholar
7b Boiron A. Zillig P. Faber D. Giese B. J. Org. Chem. 1998, 63: 5877

Google Scholar
8a Sato K. Tarui A. Kita T. Ishida Y. Tamura H. Omote M. Ando A. Kumakadi I. Tetrahedron Lett. 2004, 45: 5735

Crossref PubMed Google Scholar
8b Kanai K. Wakabayashi H. Honda T. Org. Lett. 2000, 2: 2549

Crossref PubMed Google Scholar
For information on the stereoselectivity of the hydride reduction of pyran oxoniums, see:
12a Lewis MD. Cha JK. Kishi Y. J. Am. Chem. Soc. 1982, 104: 4976

Crossref Google Scholar
12b Dondoni A. Scherrmann M.-C. J. Org. Chem. 1994, 59: 6404

Crossref Google Scholar
14a Wong C.-H. Moris-Varas F. Hung S.-C. Marron TG. Lin C.-C. Gong KW. Weitz-Schmidt G. J. Am. Chem. Soc. 1997, 119: 8152

Crossref Google Scholar
14b Kaila N. Thomas BE. Thakker P. Alvarez J. Camphausen RT. Crommie D. Bioorg. Med. Chem. Lett. 2001, 11: 151

Crossref Google Scholar

9

To a stirred solution of Wilkinson’s catalyst (0.019 g, 0.021 mmol, 0.025 equiv) in dry THF (10 mL) at 0 °C was added ethyl bromodifluoroacetate (0.144 mL, 1.22 mmol, 1.5 equiv) and a solution of dry 5-ketohexose 3a (0.437 g, 0.81 mmol, 1 equiv) in anhyd THF (13 mL). A ca. 1.0 M hexane solution of diethylzinc (2.43 mL, 2.43 mmol, 3 equiv) was then added dropwise to the mixture at 0 °C. After stirring for 1 h at this temperature, the reaction was quenched with sat. NH₄Cl (15 mL). The aqueous layer was extracted with EtOAc (3 × 15 mL) and the collected organics were washed with brine (10 mL), dried over MgSO₄ and evaporated under reduced pressure. Purification by column chromatography (6% to 10% EtOAc in cyclohexane) allowed the separation of the two diastereomers 6a (11%) and 5a (17%). R _f ( 6a) = 0.45 and R _f(5a) = 0.37 (25% EtOAc in cyclohexane).

10

To a solution of 5a (1.278 g, 1.92 mmol, 1 equiv) and Et₃SiH (6.2 mL, 38.5 mmol, 20 equiv) in CH₂Cl₂ (6 mL) was added dropwise TMSOTf (1.05 mL, 5.7 mmol, 3 equiv). The mixture was stirred at r.t. for 24 h and then neutralized with sat. NaHCO₃ (25 mL). The aqueous layer was extracted with CH₂Cl₂ (3 × 10 mL) and the collected organics were washed with brine (10 mL), dried over MgSO₄ and evaporated under reduced pressure. Purification by column chromatography (4% to 6% EtOAc in cyclohexane) afforded β-1a (54%) as a colorless oil. R _f = 0.45 (25% EtOAc in cyclohexane). [α]_D ²⁰ -21.1 (c 0.84, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.08 (t, 3 H, ³ J = 7.2 Hz), 3.46-3.50 (m, 1 H), 3.62 (dd, 1 H, ³ J = 9.3 Hz, ³ J = 2.4 Hz), 3.75-3.82 (m, 3 H), 3.92-4.03 (m, 2 H), 4.08 (t_app, 1 H, ³ J = 9.6 Hz), 4.17 (br s, 1 H), 4.49-4.97 (m, 8 H), 7.19-7.23 (m, 20 H). ¹³C NMR (75.5 MHz, CDCl₃): δ = 13.8, 62.9, 68.9,72.0 (d, ³ J = 2.9 Hz), 72.4, 73.5, 74.2, 74.6, 75.4, 77.6 (t, ² J = 28.7 Hz), 81.1, 84.0, 112.7 (dd, ¹ J = 256.4 Hz, ¹ J = 252.4 Hz), 127.4, 127.5, 127.6, 127.8, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4, 128.5, 138.0, 138.2, 138.3, 138.6, 162.9 (dd, ² J = 32.8 Hz, ² J = 29.9 Hz). ¹⁹F NMR (282.5 MHz, CDCl₃): δ = -117.2 (dd, ² J = 268.8 Hz, ³ J = 12.9 Hz), -111.4 (dd, ² J = 266.2 Hz, ³ J = 6.4 Hz). MS (ESI⁺): m/z = 669 [MNa⁺]. IR: 3032, 2915, 1767 cm^-1. Anal. Calcd for C₃₈H₄₀F₂0₇: C, 70.58; H, 6.19. Found: C, 70.41; H, 6.31.

11

The procedure described in ref. 10 was applied to 6a allowing the isolation of 7a (58%): R _f = 0.50 (25% EtOAc in cyclohexane). [α]_D ²⁰ +3.26 (c 1.50, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.10 (t, 3 H, ³ J = 7.2 Hz), 3.42-3.56 (m, 3 H), 3.60 (app t, 1 H, ³ J _app = 3.2 Hz), 3.86 (dd, ³ J = 10.0 Hz, ³ J = 2.8 Hz), 3.92-4.18 (m, 3 H), 4.21-4.59 (m, 9 H), 7.09-7.26 (m, 20 H). ¹³C NMR (75.5 MHz, CDCl₃): δ = 13.9, 62.6, 68.6,72.0, 73.1, 73.3, 73.5, 73.6 (t, ² J = 23.9 Hz), 73.8, 74.8, 75.0, 114.2, 127.8, 127.88, 127.9, 128.0, 128.1, 128.2, 128.4, 128.5, 128.6, 137.6, 138.0, 138.1, 138.2, 163.0 (t, ² J = 31.0 Hz). ¹⁹F NMR (282.5 MHz, CDCl₃): δ = -119.2 (d, ² J = 261.7 Hz), -118.2 (d, ² J = 261.7 Hz). MS (ESI⁺): m/z = 669 [MNa⁺]. IR: 3040, 2914, 1765 cm^-1. Anal. Calcd for C₃₈H₄₀F₂0₇: C, 70.58; H, 6.19. Found: C, 70.55; H, 6.18.

13

The procedure described in ref. 9 was applied to 3b allowing the isolation of 5b and 6b as an unseparable mixture (32%). This mixture was subjected to the dehydroxylation procedure described in ref. 10 to afford β-1b (23%) and 7b (35%).
Compound β-1b: R _f = 0.43 (25% EtOAc in cyclohexane). [α]_D ²⁰ +29.09 (c 1.10, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.06 (t, 3 H, ³ J = 7.2 Hz), 3.48-3.55 (m, 3 H), 3.59 (dd, 1 H, ³ J = 9.2 Hz, ³ J = 2.8 Hz), 3.80-4.02 (m, 4 H), 4.09 (t_app, 1 H, ³ J = 9.8 Hz), 4.28-4.40 (m, 2 H), 4.50-4.69 (m, 4 H), 4.83-4.89 (m, 2 H), 7.15-7.28 (m, 20 H). ¹³C NMR (75.5 MHz, CDCl₃): δ = 13.7, 62.7, 68.5, 72.3, 73.1, 73.5, 73.6, 74.5, 74.8, 77.5 (t, ² J = 23.2 Hz), 77.7, 84.3, 113.5 (t, ¹ J = 255.9 Hz), 127.6, 127.75, 127.8, 127.85, 127.9, 128.15, 128.2, 128.35, 128.4, 128.5, 137.8, 137.9, 138.0, 138.5, 162.7 (t, ² J = 31.1 Hz). ¹⁹F NMR (282.5 MHz, CDCl₃): δ = -118.3 (dd, ² J = 259.0 Hz, ³ J = 9.7 Hz), -116.7 (dd, ² J = 259.0 Hz, ³ J = 12.9 Hz). MS (ESI⁺): m/z = 669 [MNa⁺]. IR: 3034, 2920, 1768 cm^-1. Anal. Calcd for C₃₈H₄₀F₂0₇: C, 70.58; H, 6.19. Found: C, 70.69; H, 6.17.
Compound 7b: R _f = 0.50 (25% EtOAc in cyclohexane). [α]_D ²⁰ -2.65 (c 2.00, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.18 (t, 3 H, ³ J = 7.2 Hz), 3.69-3.72 (m, 1 H), 3.74-3.77 (m, 1 H), 3.79-3.84 (m, 2 H), 3.94 (dd, 1 H, ³ J = 10.0 Hz, ³ J = 2.6 Hz), 4.02 (app dt, 1 H, ³ J = 10.0 Hz, ³ J = 2.6 Hz), 4.09-4.20 (m, 2 H), 4.27-4.74 (m, 9 H), 7.15-7.39 (m, 20 H, H_ar). ¹³C NMR (75.5 MHz, CDCl₃): δ = 13.7, 62.7, 69.0, 71.7, 71.8, 72.0, 72.7, 72.9, 73.2 (d, ³ J = 2.9 Hz), 73.4, 74.2 (t, ² J = 28.2 Hz), 76.3, 113.3 (dd, ¹ J = 257.0 Hz, ¹ J = 251.8 Hz), 127.75, 127.8, 127.85, 127.9, 128.0, 128.1, 128.3, 128.4, 137.5, 137.85, 137.9, 138.6, 163.0 (dd, ² J = 33.3 Hz, ² J = 30.5 Hz). ¹⁹F NMR (282.5 MHz, CDCl₃): δ = -117.9 (dd, ² J = 267.6 Hz, ³ J = 14.0 Hz), -111.9 (dd, ² J = 267.6 Hz, ³ J = 7.5 Hz). MS (ESI⁺): m/z = 669 [MNa⁺], 685 [MK⁺]. IR: 3032, 2915, 1768 cm^-1. Anal. Calcd for C₃₈H₄₀F₂0₇: C, 70.58; H, 6.19. Found: C, 70.45; H, 6.13.